- 11,500 patients have taken it
- 400 doctors support it
- 300 scientists have written 150 scientific research papers
Successfully treats all tumour cancers-90% of cancers 75% of terminal stage IV patients lives saved.
The American National library of Medicine:
12659668 Neoplasia, 2003
- By seven cancer research institutes from three nations
- It lists six attacks of GcMAF cancer more than any other molecule.
20976141 2010 PlosOne three USA cancer institutes
- Another three attacks on cancer by GcMAF.
20855083 July of surgical research 2010
- by five of Japan’s cancer research institutes, including the prestigious atomic bomb Biomedical Institute of Nagasaki University
- GcMAF reduces liver cancer tumours by 90% in three weeks; picture in page 4; antiangiogenetic activity (cancer tumour cannot grow above 1 mm, kills tumours).
Immuno Biotech Ltd (IBL) has 33 GcMAF scientific research papers from 2013 to 2014, all peer-reviewed and published in top scientific journals.
IBL’s GcMAF become the first treatment to turn off the HER2 oncogene, and mutated gene that perpetually causes cancer throughout the patient’s short life.
25675551 Anticancer Research 2014 conference in Greece.
- Health research stored at Careggi Hospital, Florence, Italy.
Patients. gcmaf.se – click “why us” at the top
- You’ll find over 50 patient histories-recoveries from cancer and 50 incurable diseases.
And click videos
- a dozen videos of patients
Particular YouTube.com search Teri Davis Newman
- we have contact details for all of these; you can meet them-and many more.
- 200 in England.
- About 200 cancer patients were killed by the MHRA when they banned GcMAF
240 doctors bought directly from us, and about 100 recommended GcMAF. We have contact details.
We, IBL, have been utterly destroyed by the MHRA. It has big pharmaceutical directors on its board, GcMAF has been concealed for 25 years, the MHRA put David Noakes (IBL’s CEO) and one of our four scientists into Wandsworth prison to conceal it for another 25 years.